
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2882935/publications.pdf Version: 2024-02-01



IAMES REESON

#	Article	IF	CITATIONS
1	Adults with Plasmodium falciparum malaria have higher magnitude and quality of circulating T-follicular helper cells compared to children. EBioMedicine, 2022, 75, 103784.	6.1	6
2	Partnership-defined quality approach to companionship during labour and birth in East New Britain, Papua New Guinea: A mixed-methods study. PLOS Global Public Health, 2022, 2, e0000102.	1.6	3
3	Quantification of the dynamics of antibody response to malaria to inform sero-surveillance in pregnant women. Malaria Journal, 2022, 21, 75.	2.3	7
4	Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, 804470.	3.9	1
5	Quality newborn care in East New Britain, Papua New Guinea: measuring early newborn care practices and identifying opportunities for improvement. BMC Pregnancy and Childbirth, 2022, 22, .	2.4	2
6	Age-dependent changes in circulating Tfh cells influence development of functional malaria antibodies in children. Nature Communications, 2022, 13, .	12.8	6
7	Multifunctional Antibodies Are Induced by the RTS,S Malaria Vaccine and Associated With Protection in a Phase 1/2a Trial. Journal of Infectious Diseases, 2021, 224, 1128-1138.	4.0	38
8	Epitope masking may limit antibody boosting to malaria vaccines. Immunology and Cell Biology, 2021, 99, 126-129.	2.3	6
9	Structureâ€Activity Studies of Truncated Latrunculin Analogues with Antimalarial Activity. ChemMedChem, 2021, 16, 679-693.	3.2	2
10	Risk factors and knowledge associated with high unintended pregnancy rates and low family planning use among pregnant women in Papua New Guinea. Scientific Reports, 2021, 11, 1222.	3.3	15
11	RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial. Vaccine, 2021, 39, 687-698.	3.8	9
12	Complement Factors in COVID-19 Therapeutics and Vaccines. Trends in Immunology, 2021, 42, 94-103.	6.8	38
13	Framework for Characterizing Longitudinal Antibody Response in Children After Plasmodium falciparum Infection. Frontiers in Immunology, 2021, 12, 617951.	4.8	9
14	Mechanisms and targets of FcÎ ³ -receptor mediated immunity to malaria sporozoites. Nature Communications, 2021, 12, 1742.	12.8	38
15	Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of Plasmodium falciparum Is Immunogenic and Induces Functional Antibody Responses in Mice. Frontiers in Immunology, 2021, 12, 641421.	4.8	9
16	<i>Mycoplasma genitalium</i> and Other Reproductive Tract Infections in Pregnant Women, Papua New Guinea, 2015–2017. Emerging Infectious Diseases, 2021, 27, 894-904.	4.3	13
17	HIV infection and placental malaria reduce maternal transfer of multiple antimalarial antibodies in Mozambican women. Journal of Infection, 2021, 82, 45-57.	3.3	7
18	Community-based molecular and serological surveillance of subclinical malaria in Myanmar. BMC Medicine, 2021, 19, 121.	5.5	6

#	Article	IF	CITATIONS
19	High Antibodies to VAR2CSA in Response to Malaria Infection Are Associated With Improved Birthweight in a Longitudinal Study of Pregnant Women. Frontiers in Immunology, 2021, 12, 644563.	4.8	3
20	Reduced risk of placental parasitemia associated with complement fixation on Plasmodium falciparum by antibodies among pregnant women. BMC Medicine, 2021, 19, 201.	5.5	10
21	Recent clinical trials inform the future for malaria vaccines. Communications Medicine, 2021, 1, .	4.2	12
22	839A novel approach to investigating poor growth in a longitudinal study of infants in PNG. International Journal of Epidemiology, 2021, 50, .	1.9	0
23	Multi-functional antibody profiling for malaria vaccine development and evaluation. Expert Review of Vaccines, 2021, 20, 1257-1272.	4.4	13
24	Antibody Targets and Properties for Complement-Fixation Against the Circumsporozoite Protein in Malaria Immunity. Frontiers in Immunology, 2021, 12, 775659.	4.8	12
25	Complement in malaria immunity and vaccines. Immunological Reviews, 2020, 293, 38-56.	6.0	36
26	Retargeting azithromycin analogues to have dual-modality antimalarial activity. BMC Biology, 2020, 18, 133.	3.8	13
27	Sero-epidemiological evaluation of malaria transmission in The Gambia before and after mass drug administration. BMC Medicine, 2020, 18, 331.	5.5	17
28	Identifying and combating the impacts of COVID-19 on malaria. BMC Medicine, 2020, 18, 239.	5.5	84
29	Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia. BMC Medicine, 2020, 18, 304.	5.5	25
30	Evaluation of the effectiveness of topical repellent distributed by village health volunteer networks againstÂPlasmodium spp. infection in Myanmar: AÂstepped-wedge cluster randomised trial. PLoS Medicine, 2020, 17, e1003177.	8.4	16
31	Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique. Npj Vaccines, 2020, 5, 46.	6.0	15
32	Iron Deficiency Is Associated With Reduced Levels of Plasmodium falciparum-specific Antibodies in African Children. Clinical Infectious Diseases, 2020, 73, 43-49.	5.8	8
33	Selection of Antibody Responses Associated With Plasmodium falciparum Infections in the Context of Malaria Elimination. Frontiers in Immunology, 2020, 11, 928.	4.8	17
34	Impact of a Rapid Decline in Malaria Transmission on Antimalarial IgG Subclasses and Avidity. Frontiers in Immunology, 2020, 11, 576663.	4.8	8
35	Th2-like T Follicular Helper Cells Promote Functional Antibody Production during Plasmodium falciparum Infection. Cell Reports Medicine, 2020, 1, 100157.	6.5	26
36	Strengthening routine immunization in Papua New Guinea: a cross-sectional provincial assessment of front-line services. BMC Public Health, 2020, 20, 100.	2.9	6

#	Article	IF	CITATIONS
37	Understanding the interactions between iron supplementation, infectious disease and adverse birth outcomes is essential to guide public health recommendations. BMC Medicine, 2019, 17, 153.	5.5	5
38	RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: a case-control study. BMC Medicine, 2019, 17, 157.	5.5	30
39	Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium vivax Merozoite Surface Protein 31± and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M. Journal of Infectious Diseases, 2019, 220, 1950-1961.	4.0	15
40	Antibody Reactivity to Merozoite Antigens in Ghanaian Adults Correlates With Growth Inhibitory Activity Against Plasmodium falciparum in Culture. Open Forum Infectious Diseases, 2019, 6, ofz254.	0.9	6
41	lgM in human immunity to <i>Plasmodium falciparum</i> malaria. Science Advances, 2019, 5, eaax4489.	10.3	92
42	Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha. PLoS ONE, 2019, 14, e0221394.	2.5	14
43	Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity. PLoS ONE, 2019, 14, e0221733.	2.5	21
44	Acquisition of Antibodies Against Endothelial Protein C Receptor–Binding Domains of <i>Plasmodium falciparum</i> Erythrocyte Membrane Protein 1 in Children with Severe Malaria. Journal of Infectious Diseases, 2019, 219, 808-818.	4.0	22
45	The impact of early life exposure to Plasmodium falciparum on the development of naturally acquired immunity to malaria in young Malawian children. Malaria Journal, 2019, 18, 11.	2.3	15
46	Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives. Journal of Infectious Diseases, 2019, 220, 1178-1187.	4.0	21
47	Dendritic Cell Responses and Function in Malaria. Frontiers in Immunology, 2019, 10, 357.	4.8	27
48	Differential Patterns of IgG Subclass Responses to Plasmodium falciparum Antigens in Relation to Malaria Protection and RTS,S Vaccination. Frontiers in Immunology, 2019, 10, 439.	4.8	55
49	The salt between the beans: a qualitative study of the role of auxiliary midwives in a hard-to-reach area of Myanmar. BMC Health Services Research, 2019, 19, 138.	2.2	2
50	Induction and decay of functional complement-fixing antibodies by the RTS,S malariaÂvaccine in children, and a negative impact of malaria exposure. BMC Medicine, 2019, 17, 45.	5.5	65
51	Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein. Vaccine, 2019, 37, 1674-1684.	3.8	16
52	Targets of complement-fixing antibodies in protective immunity against malaria in children. Nature Communications, 2019, 10, 610.	12.8	76
53	Different Life Cycle Stages of Plasmodium falciparum Induce Contrasting Responses in Dendritic Cells. Frontiers in Immunology, 2019, 10, 32.	4.8	9
54	Sulphadoxine-pyrimethamine plus azithromycin may improve birth outcomes through impacts on inflammation and placental angiogenesis independent of malarial infection. Scientific Reports, 2019, 9, 2260.	3.3	13

#	Article	IF	CITATIONS
55	Targeting malaria parasite invasion of red blood cells as an antimalarial strategy. FEMS Microbiology Reviews, 2019, 43, 223-238.	8.6	56
56	Challenges and strategies for developing efficacious and long-lasting malaria vaccines. Science Translational Medicine, 2019, 11, .	12.4	102
57	Antibody Targets on the Surface of <i>Plasmodium falciparum–</i> Infected Erythrocytes That Are Associated With Immunity to Severe Malaria in Young Children. Journal of Infectious Diseases, 2019, 219, 819-828.	4.0	28
58	Priority use cases for antibody-detecting assays of recent malaria exposure as tools to achieve and sustain malaria elimination. Gates Open Research, 2019, 3, 131.	1.1	43
59	Combating low birth weight due to malaria infection in pregnancy. Science Translational Medicine, 2018, 10, .	12.4	6
60	Functional Conservation of the AMA1 Host-Cell Invasion Ligand Between P. falciparum and P. vivax: A Novel Platform to Accelerate Vaccine and Drug Development. Journal of Infectious Diseases, 2018, 217, 498-507.	4.0	17
61	Human Immunization With a Polymorphic Malaria Vaccine Candidate Induced Antibodies to Conserved Epitopes That Promote Functional Antibodies to Multiple Parasite Strains. Journal of Infectious Diseases, 2018, 218, 35-43.	4.0	31
62	Proteome-wide mapping of immune features onto Plasmodium protein three-dimensional structures. Scientific Reports, 2018, 8, 4355.	3.3	18
63	Identifying Immune Correlates of Protection Against Plasmodium falciparum Through a Novel Approach to Account for Heterogeneity in Malaria Exposure. Clinical Infectious Diseases, 2018, 66, 586-593.	5.8	18
64	Loss of complement regulatory proteins on uninfected erythrocytes in vivax and falciparum malaria anemia. JCI Insight, 2018, 3, .	5.0	20
65	Effectiveness of repellent delivered through village health volunteers on malaria incidence in villages in South-East Myanmar: a stepped-wedge cluster-randomised controlled trial protocol. BMC Infectious Diseases, 2018, 18, 663.	2.9	10
66	KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization. Frontiers in Immunology, 2018, 9, 2866.	4.8	26
67	Iron deficiency during pregnancy is associated with a reduced risk of adverse birth outcomes in a malaria-endemic area in a longitudinal cohort study. BMC Medicine, 2018, 16, 156.	5.5	22
68	Multiple morbidities in pregnancy: Time for research, innovation, and action. PLoS Medicine, 2018, 15, e1002665.	8.4	24
69	Cellular dissection of malaria parasite invasion of human erythrocytes using viable Plasmodium knowlesi merozoites. Scientific Reports, 2018, 8, 10165.	3.3	26
70	Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG1–4, IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies. Malaria Journal, 2018, 17, 219.	2.3	19
71	Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. PLoS Medicine, 2018, 15, e1002606.	8.4	21
72	The potential of task shifting selected maternal interventions to auxiliary midwives in Myanmar: a mixed-method study. BMC Public Health, 2018, 18, 99.	2.9	4

#	Article	IF	CITATIONS
73	Establishment of a yeast-based VLP platform for antigen presentation. Microbial Cell Factories, 2018, 17, 17.	4.0	49
74	Effect of nutrient supplementation on the acquisition of humoral immunity to Plasmodium falciparum in young Malawian children. Malaria Journal, 2018, 17, 74.	2.3	9
75	Evaluating antibody functional activity and strain-specificity of vaccine candidates for malaria in pregnancy using in vitro phagocytosis assays. Parasites and Vectors, 2018, 11, 69.	2.5	16
76	Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children. BMC Medicine, 2018, 16, 61.	5.5	79
77	The Complement System Contributes to Functional Antibody-Mediated Responses Induced by Immunization with Plasmodium falciparum Malaria Sporozoites. Infection and Immunity, 2018, 86, .	2.2	51
78	Factors influencing the induction of high affinity antibodies to Plasmodium falciparum merozoite antigens and how affinity changes over time. Scientific Reports, 2018, 8, 9026.	3.3	15
79	Low Levels of Human Antibodies to Gametocyte-Infected Erythrocytes Contrasts the PfEMP1-Dominant Response to Asexual Stages in P. falciparum Malaria. Frontiers in Immunology, 2018, 9, 3126.	4.8	14
80	Antibody Responses to Antigenic Targets of Recent Exposure Are Associated With Low-Density Parasitemia in Controlled Human Plasmodium falciparum Infections. Frontiers in Microbiology, 2018, 9, 3300.	3.5	26
81	Inhibition of placental mTOR signaling provides a link between placental malaria and reduced birthweight. BMC Medicine, 2017, 15, 1.	5.5	242
82	Plasmodium vivax vaccine research – we've only just begun. International Journal for Parasitology, 2017, 47, 111-118.	3.1	49
83	Host immunity to <i>Plasmodium falciparum</i> and the assessment of emerging artemisinin resistance in a multinational cohort. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3515-3520.	7.1	78
84	Patterns of protective associations differ for antibodies to <i>P. falciparum</i> â€infected erythrocytes and merozoites in immunity against malaria in children. European Journal of Immunology, 2017, 47, 2124-2136.	2.9	21
85	Identification of Heparin Modifications and Polysaccharide Inhibitors of Plasmodium falciparum Merozoite Invasion That Have Potential for Novel Drug Development. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	25
86	Declining Malaria Transmission Differentially Impacts the Maintenance of Humoral Immunity to Plasmodium falciparum in Children. Journal of Infectious Diseases, 2017, 216, 887-898.	4.0	31
87	Sero-catalytic and Antibody Acquisition Models to Estimate Differing Malaria Transmission Intensities in Western Kenya. Scientific Reports, 2017, 7, 16821.	3.3	15
88	Host age and expression of genes involved in red blood cell invasion in Plasmodium falciparum field isolates. Scientific Reports, 2017, 7, 4717.	3.3	3
89	Prevention of postpartum haemorrhage by community-based auxiliary midwives in hard-to-reach areas of Myanmar: a qualitative inquiry into acceptability and feasibility of task shifting. BMC Pregnancy and Childbirth, 2017, 17, 146.	2.4	14
90	Differing rates of antibody acquisition to merozoite antigens in malaria: implications for immunity and surveillance. Journal of Leukocyte Biology, 2017, 101, 913-925.	3.3	41

#	Article	IF	CITATIONS
91	Determinants of knowledge of critical danger signs, safe childbirth and immediate newborn care practices among auxiliary midwives: a cross sectional survey in Myanmar. BMJ Open, 2017, 7, e017180.	1.9	8
92	Declining Transmission and Immunity to Malaria and Emerging Artemisinin Resistance in Thailand: A Longitudinal Study. Journal of Infectious Diseases, 2017, 216, 723-731.	4.0	15
93	The exported chaperone Hsp70-x supports virulence functions for Plasmodium falciparum blood stage parasites. PLoS ONE, 2017, 12, e0181656.	2.5	45
94	Impaired placental autophagy in placental malaria. PLoS ONE, 2017, 12, e0187291.	2.5	22
95	Dichotomous miR expression and immune responses following primary blood-stage malaria. JCI Insight, 2017, 2, .	5.0	29
96	The potential benefit of scaling up malaria prevention to reduce low birth weight in Africa. PLoS Medicine, 2017, 14, e1002244.	8.4	4
97	Acquisition, maintenance and adaptation of invasion inhibitory antibodies against Plasmodium falciparum invasion ligands involved in immune evasion. PLoS ONE, 2017, 12, e0182187.	2.5	10
98	P. falciparum infection and maternofetal antibody transfer in malaria-endemic settings of varying transmission. PLoS ONE, 2017, 12, e0186577.	2.5	17
99	Antibody Responses to Plasmodium falciparum and Plasmodium vivax and Prospective Risk of Plasmodium spp. Infection Postpartum. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1197-1204.	1.4	1
100	Association between malaria immunity and pregnancy outcomes among Malawian pregnant women receiving nutrient supplementation. Malaria Journal, 2016, 15, 547.	2.3	8
101	A malaria vaccine in children with HIV. Lancet Infectious Diseases, The, 2016, 16, 1087-1089.	9.1	0
102	Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite. Infection and Immunity, 2016, 84, 2689-2696.	2.2	14
103	Immunity to malaria in an era of declining malaria transmission. Parasitology, 2016, 143, 139-153.	1.5	66
104	The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria. Scientific Reports, 2016, 6, 33094.	3.3	59
105	Evaluating Complement-Mediated Humoral Immunity to P. falciparum Blood Stages. EBioMedicine, 2016, 14, 9-10.	6.1	2
106	High resolution FTIR imaging provides automated discrimination and detection of single malaria parasite infected erythrocytes on glass. Faraday Discussions, 2016, 187, 341-352.	3.2	45
107	A single point in protein trafficking by Plasmodium falciparum determines the expression of major antigens on the surface of infected erythrocytes targeted by human antibodies. Cellular and Molecular Life Sciences, 2016, 73, 4141-4158.	5.4	20
108	Merozoite Antigens of Plasmodium falciparum Elicit Strain-Transcending Opsonizing Immunity. Infection and Immunity, 2016, 84, 2175-2184.	2.2	39

#	Article	IF	CITATIONS
109	The global threat of Zika virus to pregnancy: epidemiology, clinical perspectives, mechanisms, and impact. BMC Medicine, 2016, 14, 112.	5.5	78
110	Functional Antibodies and Protection against Blood-stage Malaria. Trends in Parasitology, 2016, 32, 887-898.	3.3	101
111	Structure–Activity Studies of β-Hairpin Peptide Inhibitors of the Plasmodium falciparum AMA1–RON2 Interaction. Journal of Molecular Biology, 2016, 428, 3986-3998.	4.2	22
112	Truncated Latrunculins as Actin Inhibitors Targeting <i>Plasmodium falciparum</i> Motility and Host Cell Invasion. Journal of Medicinal Chemistry, 2016, 59, 10994-11005.	6.4	13
113	Antibody responses to Plasmodium falciparum and Plasmodium vivax blood-stage and sporozoite antigens in the postpartum period. Scientific Reports, 2016, 6, 32159.	3.3	6
114	Maternal-foetal transfer of Plasmodium falciparum and Plasmodium vivax antibodies in a low transmission setting. Scientific Reports, 2016, 6, 20859.	3.3	13
115	A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens. BMC Medicine, 2016, 14, 144.	5.5	17
116	Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2. Scientific Reports, 2016, 6, 20613.	3.3	16
117	Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort. Vaccine Journal, 2016, 23, 104-116.	3.1	24
118	Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria. FEMS Microbiology Reviews, 2016, 40, 343-372.	8.6	275
119	Malaria and immunity during pregnancy and postpartum: a tale of two species. Parasitology, 2015, 142, 999-1015.	1.5	38
120	Malaria and Age Variably but Critically Control Hepcidin Throughout Childhood in Kenya. EBioMedicine, 2015, 2, 1478-1486.	6.1	26
121	The impact of lipid-based nutrient supplementation on anti-malarial antibodies in pregnant women in a randomized controlled trial. Malaria Journal, 2015, 14, 193.	2.3	15
122	Risk factors for malaria and adverse birth outcomes in a prospective cohort of pregnant women resident in a high malaria transmission area of Papua New Guinea. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, 109, 313-324.	1.8	45
123	Plasmodium vivax Malaria. Pediatric Infectious Disease Journal, 2015, 34, 529-531.	2.0	14
124	Acquisition of Antibodies against Plasmodium falciparum Merozoites and Malaria Immunity in Young Children and the Influence of Age, Force of Infection, and Magnitude of Response. Infection and Immunity, 2015, 83, 646-660.	2.2	121
125	PfRH5 as a candidate vaccine for Plasmodium falciparum malaria. Trends in Parasitology, 2015, 31, 87-88.	3.3	16
126	Acquisition of Functional Antibodies That Block the Binding of Erythrocyte-Binding Antigen 175 and Protection Against <i>Plasmodium falciparum</i> Malaria in Children. Clinical Infectious Diseases, 2015, 61, 1244-1252.	5.8	29

#	Article	IF	CITATIONS
127	Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Molecular Immunology, 2015, 67, 171-182.	2.2	263
128	Human Antibodies Fix Complement to Inhibit Plasmodium falciparum Invasion of Erythrocytes andÂAre Associated with Protection against Malaria. Immunity, 2015, 42, 580-590.	14.3	250
129	Designing malaria vaccines to circumvent antigen variability. Vaccine, 2015, 33, 7506-7512.	3.8	54
130	Maximizing antimalarial efficacy and the importance of dosing strategies. BMC Medicine, 2015, 13, 110.	5.5	8
131	Macrolides rapidly inhibit red blood cell invasion by the human malaria parasite, Plasmodium falciparum. BMC Biology, 2015, 13, 52.	3.8	64
132	CD14hiCD16+ monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so. BMC Medicine, 2015, 13, 154.	5.5	43
133	Novel serologic biomarkers provide accurate estimates of recent <i>Plasmodium falciparum</i> exposure for individuals and communities. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4438-47.	7.1	188
134	Malaria eradication and elimination: views on how to translate a vision into reality. BMC Medicine, 2015, 13, 167.	5.5	101
135	Differences in affinity of monoclonal and naturally acquired polyclonal antibodies against Plasmodium falciparum merozoite antigens. BMC Microbiology, 2015, 15, 133.	3.3	13
136	Conformational Dynamics and Antigenicity in the Disordered Malaria Antigen Merozoite Surface Protein 2. PLoS ONE, 2015, 10, e0119899.	2.5	27
137	Insights into the Immunological Properties of Intrinsically Disordered Malaria Proteins Using Proteome Scale Predictions. PLoS ONE, 2015, 10, e0141729.	2.5	45
138	Research priorities for the development and implementation of serological tools for malaria surveillance. F1000prime Reports, 2014, 6, 100.	5.9	56
139	Use of Immunodampening To Overcome Diversity in the Malarial Vaccine Candidate Apical Membrane Antigen 1. Infection and Immunity, 2014, 82, 4707-4717.	2.2	10
140	Immunological markers of Plasmodium vivaxexposure and immunity: a systematic review and meta-analysis. BMC Medicine, 2014, 12, 150.	5.5	66
141	Limited antigenic diversity of Plasmodium falciparumapical membrane antigen 1 supports the development of effective multi-allele vaccines. BMC Medicine, 2014, 12, 183.	5.5	47
142	Decreasing Malaria Prevalence and Its Potential Consequences for Immunity in Pregnant Women. Journal of Infectious Diseases, 2014, 210, 1444-1455.	4.0	22
143	Subclass responses and their half-lives for antibodies against EBA175 and PfRh2 in naturally acquired immunity against Plasmodium falciparum malaria. Malaria Journal, 2014, 13, 425.	2.3	19
144	Opsonic phagocytosis of Plasmodium falciparummerozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Medicine, 2014, 12, 108.	5.5	206

#	Article	IF	CITATIONS
145	Sequential Processing of Merozoite Surface Proteins during and after Erythrocyte Invasion by Plasmodium falciparum. Infection and Immunity, 2014, 82, 924-936.	2.2	60
146	A critical evaluation of pyrrolo[2,3-d]pyrimidine-4-amines as Plasmodium falciparum apical membrane antigen 1 (AMA1) inhibitors. MedChemComm, 2014, 5, 1500-1506.	3.4	8
147	Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates. Cellular and Molecular Life Sciences, 2014, 71, 3633-3657.	5.4	131
148	PTEX is an essential nexus for protein export in malaria parasites. Nature, 2014, 511, 587-591.	27.8	230
149	Antibody Boosting and Longevity Following Tetanus Immunization During Pregnancy. Clinical Infectious Diseases, 2013, 56, 749-750.	5.8	6
150	New approaches to studying Plasmodium falciparum merozoite invasion and insights into invasion biology. International Journal for Parasitology, 2013, 43, 1-10.	3.1	36
151	PfEMP1 as a target of human immunity and a vaccine candidate against malaria. Expert Review of Vaccines, 2013, 12, 105-108.	4.4	17
152	Overcoming Antigenic Diversity by Enhancing the Immunogenicity of Conserved Epitopes on the Malaria Vaccine Candidate Apical Membrane Antigen-1. PLoS Pathogens, 2013, 9, e1003840.	4.7	76
153	Defining the Timing of Action of Antimalarial Drugs against Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2013, 57, 1455-1467.	3.2	125
154	Acquired Antibodies to Merozoite Antigens in Children from Uganda with Uncomplicated or Severe Plasmodium falciparum Malaria. Vaccine Journal, 2013, 20, 1170-1180.	3.1	11
155	Erythrocyte-Binding Antigens of <i>Plasmodium falciparum</i> Are Targets of Human Inhibitory Antibodies and Function To Evade Naturally Acquired Immunity. Journal of Immunology, 2013, 191, 785-794.	0.8	62
156	Identification and Prioritization of Merozoite Antigens as Targets of Protective Human Immunity to <i>Plasmodium falciparum</i> Malaria for Vaccine and Biomarker Development. Journal of Immunology, 2013, 191, 795-809.	0.8	213
157	Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines. BMC Medicine, 2013, 11, 232.	5.5	13
158	Antibodies to Polymorphic Invasion-Inhibitory and Non-Inhibitory Epitopes of Plasmodium falciparum Apical Membrane Antigen 1 in Human Malaria. PLoS ONE, 2013, 8, e68304.	2.5	29
159	Does Malaria Affect Placental Development? Evidence from In Vitro Models. PLoS ONE, 2013, 8, e55269.	2.5	24
160	Intermittent Preventive Treatment for Malaria in Papua New Guinean Infants Exposed to Plasmodium falciparum and P. vivax: A Randomized Controlled Trial. PLoS Medicine, 2012, 9, e1001195.	8.4	38
161	Antigenic Characterization of an Intrinsically Unstructured Protein, Plasmodium falciparum Merozoite Surface Protein 2. Infection and Immunity, 2012, 80, 4177-4185.	2.2	33
162	New Insights into Acquisition, Boosting, and Longevity of Immunity to Malaria in Pregnant Women. Journal of Infectious Diseases, 2012, 206, 1612-1621.	4.0	85

#	Article	IF	CITATIONS
163	Malaria Parasite Signal Peptide Peptidase is an <scp>ER</scp> â€Resident Protease Required for Growth but not for Invasion. Traffic, 2012, 13, 1457-1465.	2.7	27
164	Platelet Factor 4 and Duffy Antigen Required for Platelet Killing of <i>Plasmodium falciparum</i> . Science, 2012, 338, 1348-1351.	12.6	141
165	Perspectives: The missing pieces. Nature, 2012, 484, S22-S23.	27.8	10
166	The Plasmodium falciparum Erythrocyte Invasion Ligand Pfrh4 as a Target of Functional and Protective Human Antibodies against Malaria. PLoS ONE, 2012, 7, e45253.	2.5	51
167	Targets of antibodies against Plasmodium falciparum–infected erythrocytes in malaria immunity. Journal of Clinical Investigation, 2012, 122, 3227-3238.	8.2	187
168	Antibody to P. falciparum in Pregnancy Varies with Intermittent Preventive Treatment Regime and Bed Net Use. PLoS ONE, 2012, 7, e29874.	2.5	18
169	High Affinity Antibodies to Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Malaria. PLoS ONE, 2012, 7, e32242.	2.5	49
170	Plasmodium vivax Adherence to Placental Glycosaminoglycans. PLoS ONE, 2012, 7, e34509.	2.5	70
171	Defining the Antigenic Diversity of Plasmodium falciparum Apical Membrane Antigen 1 and the Requirements for a Multi-Allele Vaccine against Malaria. PLoS ONE, 2012, 7, e51023.	2.5	65
172	Super-Resolution Dissection of Coordinated Events during Malaria Parasite Invasion of the Human Erythrocyte. Cell Host and Microbe, 2011, 9, 9-20.	11.0	303
173	IgC against Plasmodium falciparum variant surface antigens and growth inhibitory antibodies in Mozambican children receiving intermittent preventive treatment with sulfadoxine-pyrimethamine. Immunobiology, 2011, 216, 793-802.	1.9	7
174	A Phase 1 Trial of MSP2-C1, a Blood-Stage Malaria Vaccine Containing 2 Isoforms of MSP2 Formulated with Montanide® ISA 720. PLoS ONE, 2011, 6, e24413.	2.5	88
175	Quantifying the Importance of MSP1-19 as a Target of Growth-Inhibitory and Protective Antibodies against Plasmodium falciparum in Humans. PLoS ONE, 2011, 6, e27705.	2.5	49
176	Discovery of GAMA, a Plasmodium falciparum Merozoite Micronemal Protein, as a Novel Blood-Stage Vaccine Candidate Antigen. Infection and Immunity, 2011, 79, 4523-4532.	2.2	69
177	Reticulocyte and Erythrocyte Binding-Like Proteins Function Cooperatively in Invasion of Human Erythrocytes by Malaria Parasites. Infection and Immunity, 2011, 79, 1107-1117.	2.2	132
178	Placental Malaria-Associated Inflammation Disturbs the Insulin-like Growth Factor Axis of Fetal Growth Regulation. Journal of Infectious Diseases, 2011, 203, 561-569.	4.0	75
179	Intermittent Preventive Treatment to Reduce the Burden of Malaria in Children: New Evidence on Integration and Delivery. PLoS Medicine, 2011, 8, e1000410.	8.4	5
180	Antibodies to a Full-Length VAR2CSA Immunogen Are Broadly Strain-Transcendent but Do Not Cross-Inhibit Different Placental-Type Parasite Isolates. PLoS ONE, 2011, 6, e16622.	2.5	40

#	Article	IF	CITATIONS
181	Interactions with heparin-like molecules during erythrocyte invasion by Plasmodium falciparum merozoites. Blood, 2010, 115, 4559-4568.	1.4	154
182	Minimal Association of Common Red Blood Cell Polymorphisms with Plasmodium falciparum Infection and Uncomplicated Malaria in Papua New Guinean School Children. American Journal of Tropical Medicine and Hygiene, 2010, 83, 828-833.	1.4	24
183	Evidence That the Erythrocyte Invasion Ligand PfRh2 is a Target of Protective Immunity against <i>Plasmodium falciparum</i> Malaria. Journal of Immunology, 2010, 185, 6157-6167.	0.8	84
184	Complement receptor 1 is the host erythrocyte receptor for <i>Plasmodium falciparum</i> PfRh4 invasion ligand. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17327-17332.	7.1	182
185	Association between Naturally Acquired Antibodies to Erythrocyteâ€Binding Antigens of <i>Plasmodium falciparum</i> and Protection from Malaria and Highâ€Density Parasitemia. Clinical Infectious Diseases, 2010, 51, e50-e60.	5.8	184
186	Immunization with VAR2CSA-DBL5 Recombinant Protein Elicits Broadly Cross-Reactive Antibodies to Placental <i>Plasmodium falciparum</i> -Infected Erythrocytes. Infection and Immunity, 2010, 78, 2248-2256.	2.2	34
187	Antibodies to Chondroitin Sulfate A–Binding Infected Erythrocytes: Dynamics and Protection during Pregnancy in Women Receiving Intermittent Preventive Treatment. Journal of Infectious Diseases, 2010, 201, 1316-1325.	4.0	35
188	Evaluation of the Antigenic Diversity of Placenta-Binding <i>Plasmodium falciparum</i> Variants and the Antibody Repertoire among Pregnant Women. Infection and Immunity, 2010, 78, 1963-1978.	2.2	51
189	Isolation of viable <i>Plasmodium falciparum</i> merozoites to define erythrocyte invasion events and advance vaccine and drug development. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14378-14383.	7.1	262
190	The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis. PLoS Medicine, 2010, 7, e1000218.	8.4	306
191	Using an Improved Phagocytosis Assay to Evaluate the Effect of HIV on Specific Antibodies to Pregnancy-Associated Malaria. PLoS ONE, 2010, 5, e10807.	2.5	52
192	Development of fluorescent Plasmodium falciparum for in vitro growth inhibition assays. Malaria Journal, 2010, 9, 152.	2.3	91
193	Antibodies to Reticulocyte Binding Protein-Like Homologue 4 Inhibit Invasion of <i>Plasmodium falciparum</i> into Human Erythrocytes. Infection and Immunity, 2009, 77, 2427-2435.	2.2	65
194	Sir2 Paralogues Cooperate to Regulate Virulence Genes and Antigenic Variation in Plasmodium falciparum. PLoS Biology, 2009, 7, e1000084.	5.6	211
195	Cellular Tumor Necrosis Factor, Gamma Interferon, and Interleukin-6 Responses as Correlates of Immunity and Risk of Clinical <i>Plasmodium falciparum</i> Malaria in Children from Papua New Guinea. Infection and Immunity, 2009, 77, 3033-3043.	2.2	84
196	Strain-Specific Duffy Binding Protein Antibodies Correlate with Protection against Infection with Homologous Compared to Heterologous <i>Plasmodium vivax</i> Strains in Papua New Guinean Children. Infection and Immunity, 2009, 77, 4009-4017.	2.2	84
197	Immunoglobulin G Subclass-Specific Responses against <i>Plasmodium falciparum</i> Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness. Infection and Immunity, 2009, 77, 1165-1174.	2.2	235
198	Reticulocyte-binding protein homologue 5 – An essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. International Journal for Parasitology, 2009, 39, 371-380.	3.1	222

#	Article	IF	CITATIONS
199	Analysis of structure and function of the giant protein Pf332 in <i>Plasmodium falciparum</i> . Molecular Microbiology, 2009, 71, 48-65.	2.5	36
200	The future for bloodâ€stage vaccines against malaria. Immunology and Cell Biology, 2009, 87, 377-390.	2.3	181
201	Recent insights into humoral and cellular immune responses against malaria. Trends in Parasitology, 2008, 24, 578-584.	3.3	100
202	Truncation of Plasmodium berghei merozoite surface protein 8 does not affect in vivo blood-stage development. Molecular and Biochemical Parasitology, 2008, 159, 69-72.	1.1	8
203	Characterization of VAR2CSA-deficient Plasmodium falciparum-infected erythrocytes selected for adhesion to the BeWo placental cell line. Malaria Journal, 2008, 7, 51.	2.3	15
204	Exported Proteins Required for Virulence and Rigidity of Plasmodium falciparum-Infected Human Erythrocytes. Cell, 2008, 134, 48-61.	28.9	450
205	Estimating the Burden of Global Mortality in Children Aged <5 Years by Pathogenâ€ S pecific Causes. Clinical Infectious Diseases, 2008, 46, 1794-1795.	5.8	23
206	Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. Journal of Clinical Investigation, 2008, 118, 342-351.	8.2	166
207	Polymorphic and Conserved Targets of Antibodies againstPlasmodium falciparumduring Pregnancy. Journal of Infectious Diseases, 2008, 197, 1350-1351.	4.0	6
208	Antibody-Mediated Growth Inhibition of Plasmodium falciparum: Relationship to Age and Protection from Parasitemia in Kenyan Children and Adults. PLoS ONE, 2008, 3, e3557.	2.5	72
209	Acquisition of Growth-Inhibitory Antibodies against Blood-Stage Plasmodium falciparum. PLoS ONE, 2008, 3, e3571.	2.5	88
210	Serum Lipoproteins Promote Efficient Presentation of the Malaria Virulence Protein PfEMP1 at the Erythrocyte Surface. Eukaryotic Cell, 2007, 6, 1584-1594.	3.4	40
211	Structural Basis for Binding of Plasmodium falciparum Erythrocyte Membrane Protein 1 to Chondroitin Sulfate and Placental Tissue and the Influence of Protein Polymorphisms on Binding Specificity*. Journal of Biological Chemistry, 2007, 282, 22426-22436.	3.4	30
212	Skeleton-binding protein 1 functions at the parasitophorous vacuole membrane to traffic PfEMP1 to the Plasmodium falciparum–infected erythrocyte surface. Blood, 2007, 109, 1289-1297.	1.4	138
213	Towards a Vaccine against Plasmodium vivax Malaria. PLoS Medicine, 2007, 4, e350.	8.4	30
214	THE RISK OF MALARIAL INFECTIONS AND DISEASE IN PAPUA NEW GUINEAN CHILDREN. American Journal of Tropical Medicine and Hygiene, 2007, 76, 997-1008.	1.4	149
215	Antibodies among Men and Children to Placental-Binding Plasmodium falciparum-Infected Erythrocytes that Express var2csa. American Journal of Tropical Medicine and Hygiene, 2007, 77, 22-28.	1.4	44
216	The risk of malarial infections and disease in Papua New Guinean children. American Journal of Tropical Medicine and Hygiene, 2007, 76, 997-1008.	1.4	106

#	Article	IF	CITATIONS
217	Antibodies among men and children to placental-binding Plasmodium falciparum-infected erythrocytes that express var2csa. American Journal of Tropical Medicine and Hygiene, 2007, 77, 22-8.	1.4	35
218	A var gene promoter controls allelic exclusion of virulence genes in Plasmodium falciparum malaria. Nature, 2006, 439, 1004-1008.	27.8	245
219	Antigenic Differences and Conservation among PlacentalPlasmodium falciparum–Infected Erythrocytes and Acquisition of Variantâ€Specific and Crossâ€Reactive Antibodies. Journal of Infectious Diseases, 2006, 193, 721-730.	4.0	57
220	Development and Optimization of High-Throughput Methods To Measure Plasmodium falciparum-Specific Growth Inhibitory Antibodies. Journal of Clinical Microbiology, 2006, 44, 1665-1673.	3.9	112
221	Broad analysis reveals a consistent pattern ofvargene transcription inPlasmodium falciparumrepeatedly selected for a defined adhesion phenotype. Molecular Microbiology, 2005, 56, 774-788.	2.5	89
222	Promising Functional Readouts of Immunity in a Blood-Stage Malaria Vaccine Trial. PLoS Medicine, 2005, 2, e380.	8.4	7
223	Cross-Reactive Surface Epitopes on Chondroitin Sulfate A-Adherent Plasmodium falciparum-Infected Erythrocytes Are Associated with Transcription of var2csa. Infection and Immunity, 2005, 73, 2848-2856.	2.2	47
224	Targets of Protective Antibodies to Malaria during Pregnancy. Journal of Infectious Diseases, 2005, 192, 1647-1650.	4.0	13
225	The Immunology and Pathogenesis of Malaria During Pregnancy. , 2005, 297, 187-227.		75
226	Placental Malaria Induces Variant-Specific Antibodies of the Cytophilic Subtypes Immunoglobulin G1 (IgG1) and IgG3 That Correlate with Adhesion Inhibitory Activity. Infection and Immunity, 2005, 73, 5903-5907.	2.2	55
227	Plasmodium falciparum–Infected Erythrocytes Demonstrate Dual Specificity for Adhesion to Hyaluronic Acid and Chondroitin Sulfate A and Have Distinct Adhesive Properties. Journal of Infectious Diseases, 2004, 189, 169-179.	4.0	67
228	Antibodies to Variant Surface Antigens ofPlasmodium falciparum–Infected Erythrocytes and Adhesion Inhibitory Antibodies Are Associated with Placental Malaria and Have Overlapping and Distinct Targets. Journal of Infectious Diseases, 2004, 189, 540-551.	4.0	101
229	Phenotypes of Plasmodium falciparum from the Peripheral Blood of Pregnant Women. Infection and Immunity, 2004, 72, 1841-1841.	2.2	0
230	Malaria in pregnancy and the endemicity spectrum: what can we learn?. Trends in Parasitology, 2004, 20, 425-432.	3.3	145
231	Clinical features and pathogenesis of severe malaria. Trends in Parasitology, 2004, 20, 597-603.	3.3	275
232	Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet, The, 2004, 363, 1860-1867.	13.7	139
233	The Structural Motif in Chondroitin Sulfate for Adhesion ofPlasmodium falciparum-infected Erythrocytes Comprises Disaccharide Units of 4-O-Sulfated and Non-sulfated N-Acetylgalactosamine Linked to Glucuronic Acid. Journal of Biological Chemistry, 2002, 277, 22438-22446.	3.4	63
234	Selective Accumulation of Mature Asexual Stages of Plasmodium falciparum -Infected Erythrocytes in the Placenta. Infection and Immunity, 2002, 70, 5412-5415.	2.2	73

#	Article	IF	CITATIONS
235	Evaluating specific adhesion of Plasmodium falciparum-infected erythrocytes to immobilised hyaluronic acid with comparison to binding of mammalian cells. International Journal for Parasitology, 2002, 32, 1245-1252.	3.1	19
236	Expanding the paradigms of placental malaria. Trends in Parasitology, 2002, 18, 145-147.	3.3	11
237	Of mothers and malaria. Trends in Parasitology, 2002, 18, 420.	3.3	0
238	Pathogenesis of Plasmodium falciparum malaria: the roles of parasite adhesion and antigenic variation. Cellular and Molecular Life Sciences, 2002, 59, 258-271.	5.4	114
239	New agents to combat malaria. Nature Medicine, 2001, 7, 149-150.	30.7	24
240	Parasite adhesion and immune evasion in placental malaria. Trends in Parasitology, 2001, 17, 331-337.	3.3	58
241	Inhibition of Adhesion of Plasmodium falciparum-Infected Erythrocytes by Structurally Defined Hyaluronic Acid Dodecasaccharides. Infection and Immunity, 2001, 69, 420-425.	2.2	37
242	Adhesion of Plasmodium falciparum-infected erythrocytes to hyaluronic acid in placental malaria. Nature Medicine, 2000, 6, 86-90.	30.7	275
243	Identification of Glycosaminoglycan Binding Domains in Plasmodium falciparum Erythrocyte Membrane Protein 1 of a Chondroitin Sulfate A-Adherent Parasite. Infection and Immunity, 2000, 68, 3923-3926.	2.2	42
244	<i>Plasmodium falciparum</i> Rosette Formation Is Uncommon in Isolates from Pregnant Women. Infection and Immunity, 2000, 68, 391-393.	2.2	29
245	Plasmodium falciparumIsolates from Infected Pregnant Women and Children Are Associated with Distinct Adhesive and Antigenic Properties. Journal of Infectious Diseases, 1999, 180, 464-472.	4.0	244
246	The adhesion of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A is mediated by P. falciparum erythrocyte membrane protein 1. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5198-5202.	7.1	236
247	The placenta in malaria: mechanisms of infection, disease and foetal morbidity. Annals of Tropical Medicine and Parasitology, 1999, 93, S35-S42.	1.6	17
248	Inhibition of Binding of Malaria-Infected Erythrocytes by a Tetradecasaccharide Fraction from Chondroitin Sulfate A. Infection and Immunity, 1998, 66, 3397-3402.	2.2	53
249	Age and damage induced changes in amyloid protein precursor immunohistochemistry in the rat brain. Journal of Comparative Neurology, 1994, 342, 69-77.	1.6	48
250	Differential distribution of amyloid protein precursor immunoreactivity in the rat brain studied by using five different antibodies. Journal of Comparative Neurology, 1994, 342, 78-96.	1.6	31
251	Comparison of antibody responses and parasite clearance in artemisinin therapeutic efficacy studies in Democratic Republic of Congo and Asia. Journal of Infectious Diseases, 0, , .	4.0	1
252	Antibody dynamics in children with first or repeat Plasmodium falciparum infections. Frontiers in Medicine, 0, 9, .	2.6	1